-
Je něco špatně v tomto záznamu ?
Virtual screening, ADMET profiling, molecular docking and dynamics approaches to search for potent selective natural molecules based inhibitors against metallothionein-III to study Alzheimer's disease
S. Roy, A. Kumar, MH. Baig, M. Masařík, I. Provazník,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- Alzheimerova nemoc metabolismus patologie MeSH
- biofyzikální jevy MeSH
- lidé MeSH
- proteiny nervové tkáně antagonisté a inhibitory chemie MeSH
- simulace molekulární dynamiky MeSH
- simulace molekulového dockingu MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
MOTIVATION: Metallothionein-III (MT-III) displays neuro-inhibitory activity and is involved in the repair of neuronal damage. An altered expression level of MT-III suggests that it could be a mitigating factor in Alzheimer's disease (AD) neuronal dysfunction. Currently there are limited marketed drugs available against MT-III. The inhibitors are mostly pseudo-peptide based with limited ADMET. In our present study, available database InterBioScreen (natural compounds) was screened out for MT-III. Pharmacodynamics and pharmacokinetic studies were performed. Molecular docking and simulations of top hit molecules were performed to study complex stability. RESULTS: Study reveals potent selective molecules that interact and form hydrogen bonds with amino acids Ser-6 and Lys-22 are common to established melatonin inhibitors for MT-III. These include DMHMIO, MCA B and s27533 derivatives. The ADMET profiling was better with comparable interaction energy values. It includes properties like blood brain barrier, hepatotoxicity, druggability, mutagenicity and carcinogenicity. Molecular dynamics studies were performed to validate our findings.
Biotechnology Division CSIR Central Institute of Medicinal and Aromatic Plants Lucknow 226015 India
School of Biotechnology Yeungnam University Gyeongsan 712749 Republic of Korea
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020850
- 003
- CZ-PrNML
- 005
- 20160803095126.0
- 007
- ta
- 008
- 160722s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ymeth.2015.04.021 $2 doi
- 024 7_
- $a 10.1016/j.ymeth.2015.04.021 $2 doi
- 035 __
- $a (PubMed)25920949
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Roy, Sudeep $u Department of Biomedical Engineering, Faculty of Electrical Engineering and Communication, Brno University of Technology Technická 12, 61200 Brno, Czech Republic. Electronic address: roy@feec.vutbr.cz.
- 245 10
- $a Virtual screening, ADMET profiling, molecular docking and dynamics approaches to search for potent selective natural molecules based inhibitors against metallothionein-III to study Alzheimer's disease / $c S. Roy, A. Kumar, MH. Baig, M. Masařík, I. Provazník,
- 520 9_
- $a MOTIVATION: Metallothionein-III (MT-III) displays neuro-inhibitory activity and is involved in the repair of neuronal damage. An altered expression level of MT-III suggests that it could be a mitigating factor in Alzheimer's disease (AD) neuronal dysfunction. Currently there are limited marketed drugs available against MT-III. The inhibitors are mostly pseudo-peptide based with limited ADMET. In our present study, available database InterBioScreen (natural compounds) was screened out for MT-III. Pharmacodynamics and pharmacokinetic studies were performed. Molecular docking and simulations of top hit molecules were performed to study complex stability. RESULTS: Study reveals potent selective molecules that interact and form hydrogen bonds with amino acids Ser-6 and Lys-22 are common to established melatonin inhibitors for MT-III. These include DMHMIO, MCA B and s27533 derivatives. The ADMET profiling was better with comparable interaction energy values. It includes properties like blood brain barrier, hepatotoxicity, druggability, mutagenicity and carcinogenicity. Molecular dynamics studies were performed to validate our findings.
- 650 _2
- $a Alzheimerova nemoc $x metabolismus $x patologie $7 D000544
- 650 _2
- $a biofyzikální jevy $7 D055592
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a simulace molekulární dynamiky $7 D056004
- 650 _2
- $a proteiny nervové tkáně $x antagonisté a inhibitory $x chemie $7 D009419
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kumar, Akhil $u Biotechnology Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow 226015, India. Electronic address: akhil2687@gmail.com.
- 700 1_
- $a Baig, Mohd Hassan $u School of Biotechnology, Yeungnam University, Gyeongsan 712749, Republic of Korea. Electronic address: mohdhassanbaig@gmail.com.
- 700 1_
- $a Masařík, Michal $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, Bld. A18, 625 00 Brno, Czech Republic. Electronic address: masarik@med.muni.cz.
- 700 1_
- $a Provazník, Ivo $u International Clinical Research Center - Center of Biomedical Engineering, St. Anne's University Hospital Brno and Department of Biomedical Engineering, FEEC, Brno University of Technology, Brno, Czech Republic. Electronic address: ivo.provaznik@fnusa.cz.
- 773 0_
- $w MED00005029 $t Methods (San Diego, Calif.) $x 1095-9130 $g Roč. 83, č. - (2015), s. 105-10
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25920949 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20160803095356 $b ABA008
- 999 __
- $a ok $b bmc $g 1155520 $s 945378
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 83 $c - $d 105-10 $e 20150425 $i 1095-9130 $m Methods $n Methods $x MED00005029
- LZP __
- $a Pubmed-20160722
